Navigation Links
Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
Date:3/3/2010

p>

"This is an exciting continuation of our important collaboration with GSK, a leading company in cancer immunotherapy research," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.  "The agreement is indicative of our commitment to personalized medicine and our focus on developing innovative companion diagnostic tests that can be used to identify patients most likely to benefit from specific cancer therapies."

According to the Skin Cancer Foundation (http://www.skincancer.org/Melanoma), melanoma is the most serious form of skin cancer.  However, if it is recognized and treated early, it is nearly 100 percent curable.  While it is not the most common of skin cancers, it causes the most deaths.  The American Cancer Society estimates that in 2008, there were 8,420 fatalities in the U.S. alone, 5,400 in men and 3,020 in women.  The number of new cases is estimated at more than 62,000; of these, approximately 35,000 will be in men and approximately 27,000 in women.    

ASCIs and MAGE-A3 ASCI


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... host a webcast conference call to report its second ... the company,s business and outlook on Thursday, August 7, ... the market. The call can be ... (international) five minutes prior to the start of the ...
(Date:7/24/2014)... 24, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the first fiscal ... overview: , Revenues of $47.5 million, up 10% ... of $0.21, up 50% over last year,s comparable quarter. ... of $7.2 million, up 20% over last year,s comparable ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has accepted  Damian Finio,s ... has accepted a senior level finance position at a ... of his new position, Mr. Finio will be unable ... Laboratories, Inc.  The effective date of his resignation will ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... (NASDAQ: SIAL ) today announced that its ... ), is introducing a novel CHOZN® GS-/- Zinc Finger ... for use in the production of biopharmaceuticals, the new ... glutamine synthetase (GS) knockout CHO cell line proven to ...
... LAS VEGAS, Oct. 26, 2011 Clinical Research Management, ... basic and applied research, clinical trials, and regulatory support, ... Boyer, Ph.D., will co-present a panel titled Battle ... the MAGI West Clinical Research Conference, October 23-26, 2011 ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4ClinicalRM to Co-Present Regulatory Compliance Panel at MAGI 2
(Date:7/25/2014)... July 25, 2014 Ticket Down ... Inter Milan tickets in Berkeley at California Memorial Stadium. ... new fans of football, the organizers of the 2014 Guinness ... club teams to North America. With teams representing La Liga, ... will bring some of the best football players from around ...
(Date:7/25/2014)... 25, 2014 On July 22, ... Media client and the nation’s number one provider ... handbooks, announced their partnership with TransAct Merchant Solutions’ ... registered ISO/MSP of Chase Paymentech Solutions, LLC, which ... industry. Companies that are members of TransAct’s National ...
(Date:7/25/2014)... Hastings and Hastings, a personal injury ... to personal injury claims, announces free initial consultations. Hastings ... services for those that have been injured as a ... Free initial consultation services gives clients’ greater flexibility in ... personal injury claim . It also offers clients the ...
(Date:7/25/2014)... News) -- Shift workers, especially men, may be at higher ... such schedules, a new study suggests. Also at special ... schedule, with shifts moving around at various times of the ... one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox ... known that working shifts disrupts many key body chemicals, creating ...
(Date:7/25/2014)... protect vulnerable neurons and reduce motor deficits in ... Emory University School of Medicine have shown. , ... of Parkinson,s Disease . , The findings demonstrate ... brain at sufficient levels and have beneficial effects ... shot. Previous studies of XPro1595 in animals tested ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... Jan. 6 (HealthDay News) -- Weight loss surgery isn,t likely ... sugar control, a new study suggests. Obesity is a ... that gastric bypass surgery can cure diabetes in up to ... stomach to form a smaller pouch and connecting it to ...
... (HealthDay News) -- The blood pressure medicine losartan [Cozaar] ... to cigarette smoke for two months, researchers say. ... thickening, inflammation and lung overexpansion in the animals, according ... led to a clinical trial of losartan in people ...
... of New York (CCNY) whose research unites the divergent ... be honored this month for his pioneering work in ... and photonics. SPIE will present Dr. Robert Alfano, ... with the first annual Britton Chance Biomedical Optics Award ...
... Fla. (Jan. 6, 2012) A malignancy-risk gene signature ... predictive and prognostic value for patients with early stage ... researchers at Moffitt Cancer Center in Tampa, Fla., who ... the Journal of the National Cancer Institute . ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Jan. ... a U.S. advisory panel,s recommendation to lower the threshold ... metal once common in gasoline and house paint, can ... Advisory Committee on Childhood Lead Poisoning Prevention voted to ...
... By Alan Mozes HealthDay Reporter , THURSDAY, ... seniors may double their risk of developing a particularly ... disease, a large new European study suggests. The ... macular degeneration (AMD), a significant cause of blindness in ...
Cached Medicine News:Health News:Weight Loss Surgery May Help Diabetes 2Health News:Mice Exposed to Smoke Helped by Blood Pressure Drug: Study 2Health News:CCNY's Robert Alfano wins first biomedical optics award 2Health News:CCNY's Robert Alfano wins first biomedical optics award 3Health News:Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3Health News:Could Daily Aspirin Harm Seniors' Eyes? 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 3
For lipoplasty of trochanteric area, abdomen, thighs, hips, buttocks and flanks...
CDIs original garments with our exclusive Wonderfabric™....
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Black Spandex Above the Knee Compression Girdles with Hook & Eye with Zipper...
Medicine Products: